Insensitivity of Human iPS Cells-Derived Mesenchymal Stem Cells to Interferon-γ-induced HLA Expression Potentiates Repair Efficiency of Hind Limb Ischemia in Immune Humanized NOD Scid Gamma Mice

Stem Cells

Volumn 33, Issue 12, 2015, Pages 3452-3467

  Sun, Yue Qi ^a   Zhang, Yuelin ^b   Li, Xin ^c   Deng, Meng Xia ^a   Gao, Wen Xiang ^a   Yao, Yin ^a   Chiu, Sin Ming ^b   Liang, Xiaoting ^b   Gao, Fei ^b   Chan, Camie W ^b   Tse, Hung Fat ^b   Shi, Jianbo ^a   Fu, Qing Ling ^a   Lian, Qizhou ^b,d  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d UNIVERSITY OF HONG KONG   (China)

Author keywords

Human leukocyte antigen class II; Immune humanized mice; Induced pluripotent stem cells; Mesenchymal stem cells

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERFERON REGULATORY FACTOR 1; STAT1 PROTEIN; IFNG PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; FETUS; FLOW CYTOMETRY; HINDLIMB; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOSTIMULATION; INFLAMMATION; INFLAMMATORY CELL; LIMB ISCHEMIA; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NOD SCID GAMMA MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN PHOSPHORYLATION; ANIMAL; BIOSYNTHESIS; INDUCED PLURIPOTENT STEM CELL; ISCHEMIA; MESENCHYMAL STROMA CELL; METABOLISM; NONOBESE DIABETIC MOUSE; SCID MOUSE; VASCULARIZATION; XENOGRAFT;

ANIMALS; HETEROGRAFTS; HINDLIMB; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INTERFERON-GAMMA; ISCHEMIA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED NOD; MICE, SCID;

EID: 84983134611     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2094     Document Type: Article

References (46)

1. Jacobs SA, Roobrouck VD, Verfaillie CM, et al., Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunol Cell Biol 2013; 91: 32-39.
2. Gebler A, Zabel O, Seliger B,. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med 2012; 18: 128-134.
3. Bartholomew A, Patil S, Mackay A, et al., Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther 2001; 12: 1527-1541.
4. Devine SM, Bartholomew AM, Mahmud N, et al., Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001; 29: 244-255.
5. Horwitz EM, Gordon PL, Koo WK, et al., Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99: 8932-8937.
6. Muller I, Kordowich S, Holzwarth C, et al., Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008; 40: 25-32.
7. Le Blanc K, Frassoni F, Ball L, et al., Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008; 371: 1579-1586.
8. Jiang R, Han Z, Zhuo G, et al., Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: A pilot study. Front Med 2011; 5: 94-100.
9. Sun L, Akiyama K, Zhang H, et al., Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27: 1421-1432.
10. Koc ON, Gerson SL, Cooper BW, et al., Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307-316.
11. Deans RJ, Moseley AB,. Mesenchymal stem cells: Biology and potential clinical uses. Exp Hematol 2000; 28: 875-884.
12. Klyushnenkova E, Mosca JD, Zernetkina V, et al., T cell responses to allogeneic human mesenchymal stem cells: Immunogenicity, tolerance, and suppression. J Biomed Sci 2005; 12: 47-57.
13. Lian Q, Zhang Y, Zhang J, et al., Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation 2010; 121: 1113-1123.
14. Sun YQ, Deng MX, He J, et al., Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice. Stem Cells 2012; 30: 2692-2699.
15. Lian Q, Lye E, Suan Yeo K, et al., Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs. Stem Cells 2007; 25: 425-436.
16. Zhang J, Lian Q, Zhu G, et al., A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 2011; 8: 31-45.
17. Romieu-Mourez R, Francois M, Boivin MN, et al., Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J Immunol 2007; 179: 1549-1558.
18. Chan WK, Lau AS, Li JC, et al., MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. Exp Hematol 2008; 36: 1545-1555.
19. Bocelli-Tyndall C, Zajac P, Di Maggio N, et al., Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. Arthritis Rheum 2010; 62: 3815-3825.
20. Cui L, Yin S, Liu W, et al., Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. Tissue Eng 2007; 13: 1185-1195.
21. Gotherstrom C, Ringden O, Tammik C, et al., Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol 2004; 190: 239-245.
22. Fu QL, Chow YY, Sun SJ, et al., Mesenchymal stem cells derived from human induced pluripotent stem cells modulate T-cell phenotypes in allergic rhinitis. Allergy 2012; 67: 1215-1222.
23. Ali N, Flutter B, Sanchez Rodriguez R, et al., Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rgammanull mice display a T-effector memory phenotype. PLoS One 2012; 7: e44219.
24. King M, Pearson T, Shultz LD, et al., Development of new-generation HU-PBMC-NOD/SCID mice to study human islet alloreactivity. Ann N Y Acad Sci 2007; 1103: 90-93.
25. PM, SH, RM et al. Adult mesenchymal stem cells and cell surface characterization-A systematic review of the literature. Open Orthop J 2011; 5: 253-260.
26. Delamarre L, Holcombe H, Mellman I,. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med 2003; 198: 111-122.
27. Le Blanc K, Tammik C, Rosendahl K, et al., HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-896.
28. Cheng CC, Lian WS, Hsiao FS, et al., Isolation and characterization of novel murine epiphysis derived mesenchymal stem cells. PLoS One 2012; 7: e36085.
29. Liu S, Yuan M, Hou K, et al., Immune characterization of mesenchymal stem cells in human umbilical cord Wharton's jelly and derived cartilage cells. Cell Immunol 2012; 278: 35-44.
30. Buttice G, Miller J, Wang L, et al., Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells. Circ Res 2006; 98: 472-479.
31. Ilangumaran S, Finan D, La Rose J, et al., A positive regulatory role for suppressor of cytokine signaling 1 in IFN-gamma-induced MHC class II expression in fibroblasts. J Immunol 2002; 169: 5010-5020.
32. Platanias LC,. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5: 375-386.
33. Piskurich JF, Linhoff MW, Wang Y, et al., Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. Mol Cell Biol 1999; 19: 431-440.
34. Wright KL, Ting JP,. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 2006; 27: 405-412.
35. Lenschow DJ, Walunas TL, Bluestone JA,. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-258.
36. Rossignol J, Boyer C, Thinard R, et al., Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med 2009; 13: 2547-2558.
37. Francois M, Romieu-Mourez R, Stock-Martineau S, et al., Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood 2009; 114: 2632-2638.
38. Stagg J, Pommey S, Eliopoulos N, et al., Interferon-gamma-stimulated marrow stromal cells: A new type of nonhematopoietic antigen-presenting cell. Blood 2006; 107: 2570-2577.
39. Krampera M, Glennie S, Dyson J, et al., Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-3729.
40. Oh W, Kim DS, Yang YS, et al., Immunological properties of umbilical cord blood-derived mesenchymal stromal cells. Cell Immunol 2008; 251: 116-123.
41. Tse WT, Pendleton JD, Beyer WM, et al., Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003; 75: 389-397.
42. Wagner W, Bork S, Horn P, et al., Aging and replicative senescence have related effects on human stem and progenitor cells. PLoS One 2009; 4: e5846.
43. Crisostomo PR, Wang M, Wairiuko GM, et al., High passage number of stem cells adversely affects stem cell activation and myocardial protection. Shock 2006; 26: 575-580.
44. Kretlow JD, Jin YQ, Liu W, et al., Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biol 2008; 9: 60.
45. Laurent LC, Ulitsky I, Slavin I, et al., Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011; 8: 106-118.
46. Lister R, Pelizzola M, Kida YS, et al., Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471: 68-73.